Home > About Us > Press Releases > Archives
Archives
02-18-09
ReGen Biologics Initiates Training Program for U.S. Surgeons
02-17-09
ReGen Biologics Announces Closing of Additional Financing
01-21-09
ReGen Biologics Announces Common Stock Financing to Support Launch of Menaflex™ Collagen Meniscus Implant
01-12-09
Regen Biologics Launching Menaflex™ Collagen Meniscus Implant at American Academy of Orthopaedic Surgeons
12-22-08
ReGen Biologics Receives FDA 510(K) Clearance for its Collagen Scaffold Device: The Menaflex™ Collagen Meniscus Implant
12-08-08
ReGen Biologics Announces Incremental Bridge Financing
12-01-08
ReGen Biologics Announces Reverse Stock Split and New Ticker Symbol “RGBO”
11-18-08
ReGen Biologics Collagen Scaffold Receives Positive Orthopaedic Panel Recommendations
07-28-08
ReGen Biologics Closes $2.5 Million Private Placement and Announces New 510(k) Submission to the FDA
07-07-08
View JBJS Article Abstract and Download Complete Text Article
07-07-08
ReGen Biologics Announces JBJS Publication of Successful Clinical Trial Results for its Meniscus Product
04-03-08
ReGen Biologics Launches Product Distribution in the United Kingdom
04-03-08
ReGen Biologics Reports Sales Progress and Provides Business Update
12-05-07
ReGen Biologics Introduces New Brand Name and Websites
11-21-07
ReGen Biologics Enters New Markets in Poland and South Africa
08-24-07
ReGen Biologics Receives NSE Letter from FDA, Proceeding with Next Steps to Gain U.S. Market Clearance
07-08-07
ReGen Biologics to Exhibit at 2007 AOSSM Annual Meeting
06-25-07
ReGen Biologics Responds to Request for Additional Information on Pending 510(k)
05-24-07
ReGen Biologics to Launch Lateral CMI™ at 6th Biennial ISAKOS Congress
04-25-07
ReGen Biologics Participates in 2007 AANA Annual Meeting
04-04-07
ReGen Biologics Closes $2.7 Million Private Placement
03-05-07
ReGen Biologics Closes Additional $3 Million Private Placement
02-25-07
ReGen Biologics Data Presented in San Diego
02-05-07
ReGen Biologics to Present at First Albany’s Second Annual Orthopedics Conference on February 13, 2007
02-04-07
ReGen Biologics Participates in 2007 AAOS Annual Meeting
12-03-06
ReGen Biologics Completes Approximately $7 Million Private Placement
11-12-06
ReGen Biologics Announces Results of FDA Appeal
11-06-06
ReGen Biologics Announces New CMI Clinical Results
09-06-06
ReGen Biologics Provides Update on 510(k) Submission
06-19-06
ReGen Biologics Tissue Growth Data Presented
05-30-06
Regen Biologics CMI™ Topic of Symposium
05-15-06
ReGen Biologics Hosts Annual Shareholder Meeting
05-07-06
ReGen Biologics Meniscus Data To Be Presented
05-02-06
Recent Article Validates Tools Used by ReGen Biologics to Measure Meniscus Performance
04-30-06
ReGen Biologics Reports First Bilateral CMI™ Procedure
04-27-06
ReGen Biologics Provides Update on 510(K) Regulatory Submission
02-26-06
CMI™ Labeling Expanded in Europe to Include Lateral Use
01-29-06
ReGen Biologics Meniscus Data Featured in Scientific Meetings
01-03-06
ReGen Biologics Announces 510(k) Regulatory Submission in the U.S.
11-20-05
ReGen Biologics Completes Distribution Coverage in Spain with Exclusive Agreement
11-15-05
Regen Biologics Signs Exclusive Distribution Agreement for Spain
11-13-05
International Symposium Features Latest CMI™ Data
10-30-05
ReGen Biologics Signs Exclusive Distribution Agreement for Italy
08-29-05
ReGen Biologics Launches European Website
08-22-05
FDA Follows-up on Form 483 Notice of Inspectional Observations with Warning Letter
07-14-05
ReGen Biologics Completes $11.8 Million Private Placement
05-25-05
ReGen Biologics AG to Host June 6, 2005 Evening Event at EFORT Congress in Lisbon for Surgeons Interested in ReGen® CMI
05-24-05
ReGen Biologics To Present at the Pacific Growth Equities Life Science Conference in San Francisco on June 6, 2005
05-24-05
ReGen Biologics Surgeons Successfully Complete Lateral CMI™Surgeries
05-16-05
ReGen Biologics Announces Publication of Five Year Data from CMI Feasibility Study in Arthroscopy
03-17-05
ReGen Biologics Reports Select Operating Results for 2004
03-06-05
ReGen Regains Exclusive Worldwide Distribution Rights for its CMI
10-06-04
ReGen Biologics to Present at the HealthPoint Capital New York Biomaterials Summit
07-25-04
ReGen Biologics Begins Modular FDA Pre-Market Approval Submission for CMI Product
06-09-04
William R. Timken, Former Vice Chairman of Hambrecht & Quist, Named to ReGen Biologics Board of Directors
04-20-04
ReGen Biologics Completes Private Placement of Common Stock for Gross Proceeds of Approximately $10.3 Million
02-26-04
ReGen Biologics Continues Advance Towards FDA Submission with the Selection of Key FDA Consulting Firm
11-30-03
ReGen Biologics to Present at Harris Nesbitt Gerard Focus on Healthcare Conference December 11 in New York City
10-27-03
ReGen Biologics Retains Cameron Associates as Investor Relations Advisor
10-15-03
ReGen Biologics To Present At Rodman & Renshaw Techvest Healthcare Conference
09-30-03
ReGen Biologics Finalizes Private Placement Totaling $10 Million
08-22-03
ReGen Biologics Completes Private Placement
05-18-03
ReGen Biologics Appoints Abhi Acharya, Ph.D. to Board of Directors
03-18-03
ReGen Biologics Launches New Website
01-05-03
ReGen Biologics Announces 2002 Accomplishments
12-01-02
ReGen Biologics Filed U.S. Patent Application for Membrane Enforced Implant
11-21-02
ReGen Biologics CEO Interview at Ceocast.com
11-19-02
ReGen Announces Completion of CMI Clinical Trial Surgeries
11-18-02
Aros Corporation Announces Name and Ticker Change
10-21-02
German Magazine, Stern, Interviews ReGen Biologics’ Director, Dr. Richard Steadman and Highlights ReGen’s Groundbreaking Meniscal Repair Procedure
09-29-02
ReGen Obtains Approval in Australia
09-25-02
ReGen Biologics Announces the Completion of U.S. Clinical Trial Enrollments
09-22-02
Aros To Postpone Annual Meeting of Stockholders
07-18-02
ReGen CMI Featured At 3rd International Heidelberg Orthopedic Symposium
06-24-02
Aros Completes Acquisition of ReGen Biologics
07-04-00
ReGen Biologics CMI Recognized With GOTS-Beiersdorf Orthopaedic Research Award
05-10-00
ReGen Biologics Receives Financing From Sulzer Medica
04-16-00
ReGen Biologics Announces Licensing Agreement For The SharpShooter® Tissue Repair System for Meniscus Repair
04-04-00
ReGen Biologics Commences European Market Launch of CMI Through Sulzer Medica
02-21-00
ReGen Biologics Receives CE Marking for CMI
Email a friend
Print this page